Meet Kevin Pricing Power ETF News - PP

- Statement of Beneficial Ownership (SC 13D)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Pipex...

Pipex Pharmaceuticals to Present at the Maxim Group Growth Conference on October 7th

ANN ARBOR, MI -- (Marketwire) -- 10/06/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals' Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World Congress on Treatment and Re

ANN ARBOR, MI -- (Marketwire) -- 09/19/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB/A AMENDMENT No. 1 ANNUAL REPORT...

Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate for Rheumatoid Arthritis

ANN ARBOR, MI -- (Marketwire) -- 08/19/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals, Inc. to Present at the RedChip Small Cap Investor Conference in New York City

ANN ARBOR, MI -- (Marketwire) -- 08/19/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ý...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13...

Pipex Pharmaceuticals Announces Clinical Update and Second Quarter 2008 Results

ANN ARBOR, MI -- (Marketwire) -- 08/14/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals to Present at the Noble Financial Equity Conference

ANN ARBOR, MI -- (Marketwire) -- 08/12/08 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative...

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND...

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Or

ANN ARBOR, MI , a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Meet Kevin Pricing Power ETF (PP)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PP News

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals to Present at the Maxim Group Growth Conference on October 7th

Pipex Pharmaceuticals' Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World Congress on Treatment and Re

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate for Rheumatoid Arthritis

Pipex Pharmaceuticals, Inc. to Present at the RedChip Small Cap Investor Conference in New York City

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals Announces Clinical Update and Second Quarter 2008 Results

Pipex Pharmaceuticals to Present at the Noble Financial Equity Conference

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Or

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

PP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Meet Kevin Pricing Power ETF (PP) News

Meet Kevin Pricing Power ETF (PP)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PP News

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals to Present at the Maxim Group Growth Conference on October 7th

Pipex Pharmaceuticals' Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World Congress on Treatment and Re

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate for Rheumatoid Arthritis

Pipex Pharmaceuticals, Inc. to Present at the RedChip Small Cap Investor Conference in New York City

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals Announces Clinical Update and Second Quarter 2008 Results

Pipex Pharmaceuticals to Present at the Noble Financial Equity Conference

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Or

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

PP Discussion

Your Recent History